Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Initiatives are in place to develop a Finished Dosage Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses.
|
Company: |
Laurus Labs Limited | ||
|
Headquarters Address: |
2nd Floor Serene Towers, Rd No 5, Banjarahills, | ||
| Hyderabad 500034 | |||
| India | |||
|
Main Telephone: |
+91 40 3980 4333 | ||
|
Website: |
|||
|
Ticker/ISIN: |
540222(MUMBAI)/INE947Q01010 | ||
|
LAURUSLABS(NSI)/INE947Q01010 |
|||
|
Type of Organization: |
Public | ||
|
Industry: |
Pharmaceutical | ||
|
Earnings Release Dates: |
4th Quarter: May 18, 2017 |
||
|
Key Executives: |
CEO: Satyanarayana Chava |
||
|
CFO: V V Ravi Kumar |
|||
|
Public Relations |
|||
|
Contact: |
Pavan Kumar | ||
|
Phone: |
+91 40 3980 4380 | ||
|
Email: |
|||
View source version on businesswire.com: http://www.businesswire.com/news/home/20170518005424/en/